ストックスクリーナーアプリを入手
83.11
3.47%
-2.995
前日終値:
$86.11
開ける：
$85.53
24時間の取引高:
145.90K
Relative Volume:
0.15
時価総額：
$6.65B
収益：
$58.89M
当期純損益:
$-240.88M
株価収益率:
-26.81
EPS:
-3.1
ネットキャッシュフロー:
$-239.96M
1週間 パフォーマンス:
-12.53%
1か月 パフォーマンス:
+9.46%
6か月 パフォーマンス:
+91.05%
1年 パフォーマンス:
+162.22%
1日の値動き範囲:
$82.31
$86.92
1週間の範囲:
$82.31
$93.99
52週間の値動き範囲:
$19.45
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
名前
Kymera Therapeutics Inc
セクター
電話
857-285-5314
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
83.11 | 6.89B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.37 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.59 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
726.34 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.66 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
293.62 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-06 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | 再開されました | Guggenheim | Buy |
| 2025-10-24 | 繰り返されました | B. Riley Securities | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-06-03 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-05-20 | 再開されました | Stifel | Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-12-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-26 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 開始されました | Oppenheimer | Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 開始されました | Truist | Buy |
| 2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 開始されました | Raymond James | Mkt Perform |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-08-03 | 開始されました | Goldman | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | JP Morgan | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2021-09-30 | 開始されました | B. Riley Securities | Neutral |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-09-15 | 開始されました | BofA Securities | Neutral |
| 2020-09-15 | 開始されました | Cowen | Outperform |
| 2020-09-15 | 開始されました | Guggenheim | Buy |
| 2020-09-15 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Kymera Therapeutics Inc (KYMR) 最新ニュース
Q1 EPS Estimate for Kymera Therapeutics Boosted by Analyst - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 3,919 Shares - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CFO Sells 4,895 Shares of Stock - MarketBeat
Bruce Jacobs Sells 7,576 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Jared Gollob Sells 5,613 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 81,866 Shares of Stock - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Acquired by Rafferty Asset Management LLC - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $128.00 - MarketBeat
UBS Raises Price Target for Kymera Therapeutics (KYMR) to $128 | - GuruFocus
Kymera at TD Cowen Conference: Strategic Insights on Drug Programs - Investing.com
Commit To Purchase Kymera Therapeutics At $60, Earn 15.1% Annualized Using Options - Nasdaq
How Kymera’s Bigger Losses and New Equity Plans May Impact Kymera Therapeutics (KYMR) Investors - simplywall.st
Kymera Therapeutics (KYMR) Stock Analysis: Exploring a 30% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews
UBS Adjusts Price Target on Kymera Therapeutics to $128 From $90, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase (NASDAQ:KYMR) - Seeking Alpha
Citigroup Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $120.00 - MarketBeat
Kymera Therapeutics (KYMR): Citigroup Raises Price Target, Reaff - GuruFocus
Stephens raises Kymera Therapeutics price target to $100 on pipeline By Investing.com - Investing.com Canada
Kymera Therapeutics (KYMR): Analyst Raises Price Target to $100 - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $100.00 at Stephens - MarketBeat
TD Asset Management Inc Reduces Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Wider Losses And Major Equity Plans - Yahoo Finance
Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 - Yahoo Finance
Kymera Therapeutics Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Vanguard Group Inc. Cuts Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat
KYMR Should I Buy - Intellectia AI
Kymera Therapeutics Signals Strong Momentum In Earnings Call - TipRanks
Kymera Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:KYMR) 2026-02-27 - Seeking Alpha
Kymera’s KT-579 Enters First-in-Human Testing: What Early Trial Progress Means for Investors - TipRanks
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway - Finviz
Kymera Therapeutics advances oral degrader pipeline amid immunology research momentum - Traders Union
Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler - Yahoo Finance
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2025 Earnings Call Transcript - Insider Monkey
Kymera Therapeutics (KYMR) TTM Loss Of US$311 Million Tests Bullish Growth Narrative - Sahm
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results - MarketBeat
Kymera Therapeutics launches $500 million at-the-market stock offering - Investing.com Australia
Kymera Therapeutics launches $500 million at-the-market stock offering By Investing.com - Investing.com Canada
KYMR: Kymera Therapeutics Maintained Outperform by RBC Capital Feb 26 2026 - Meyka
Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ... By GuruFocus - Investing.com Canada
Kymera Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Kymera (KYMR) Q4 2025 Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Kymera Misses Q4 2025 Forecasts, Stock Drops - Investing.com
Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress - Investing.com UK
Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights: - GuruFocus
Kymera at Oppenheimer Conference: Strategic Focus on IMiD and Clinical Progress - Investing.com Canada
BTIG Maintains Buy Rating on KYMR, Lowers Price Target | KYMR St - GuruFocus
Analyst Expectations For Kymera Therapeutics's Future - Benzinga
KYMR: STAT6 and IRF5 programs advance with strong data, targeting major unmet needs in immunology - TradingView
BTIG Research Cuts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $134.00 - MarketBeat
Kymera Therapeutics Inc (KYMR) 財務データ
収益
当期純利益
現金流量
EPS
0.50%
大文字化:
|
ボリューム (24 時間):